

# KEY INFORMATION DOCUMENT



## Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

## ARK GENOMIC REVOLUTION UCITS ETF

### PRODUCT

|                      |  |
|----------------------|--|
| Product:             | ARK Genomic Revolution UCITS ETF - USD Accumulating ETF      |
| Manufacturer name:   | IQ EQ Fund Management (Ireland) Limited                      |
| ISIN:                | IE00005M6XOI   |
| Website:             | <a href="https://arkeurope.com/">https://arkeurope.com/</a>  |
| Competent Authority: | Central Bank of Ireland. This Fund is authorised in Ireland. |
| Domicile country:    | Ireland  |

Document valid as at: 29 July 2025

### WHAT IS THIS PRODUCT?

#### Type:

This product is a UCITS exchange traded fund. It is a sub-fund of ARK Invest UCITS ICAV (the "ICAV"), an open-ended Irish collective asset management vehicle with variable capital and segregated liability between its sub-funds and registered in Ireland and authorised by the Central Bank of Ireland as a UCITS.

#### Term:

This product is not subject to any fixed term.


#### Objectives:

This product is actively managed and invests primarily in global equity securities of companies involved in the genomic revolution. These are companies that are substantially focused on or benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in genomics into their business, such as by offering new products or services that rely on genomic sequencing, analysis, synthesis or instrumentation. These companies may include ones across multiple sectors, such as healthcare, information technology, materials, energy and consumer discretionary. These companies may also develop, produce, manufacture or significantly rely on or enable bionic devices, bio-inspired computing, bioinformatics, molecular medicine and agricultural biotechnology. The investment manager uses both "top down" approaches (thematic research sizing the potential total available market for each technology, and identifying the prime leaders, enablers and beneficiaries of the innovation) and "bottom up" approaches (valuation, fundamentals and quantitative measures relating to individual companies) to select companies. The "top down" approach explicitly selects for technologies that the Investment Manager anticipates will make a meaningful contribution to at least two of the United Nations Sustainable Development Goals. The "bottom up" approach to company selection integrates ESG considerations such as business involvement, violations of international norms and standards and an assessment of controversies, environmental and social risks and governance.

#### Intended Retail Investor:

A typical Investor would be one who is a private or institutional investor and is seeking capital appreciation over the long term. Such an Investor is also one that is able to assess the merits and risks of an investment in this Fund.

### WHAT ARE THE RISKS AND WHAT COULD I GET IN RETURN?



The risk indicator assumes you keep the product for 5 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less.

#### Risk indicator

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as class 6 out of 7, which the second highest risk class. This rates the potential losses from future performance at a high level, and poor market conditions are very likely to impact the capacity of the fund to pay you.

The Fund is subject to the risks associated with technology-focused companies (including biotechnology and pharmaceutical companies) including the risk of: (1) failure of new technologies and solutions to replace existing ones or to be approved by governments/regulators or to achieve their aim; (2) the failure of individual companies to successfully capitalise on such new technologies and reach profitability; (3) competition, including rapid developments in competitive technologies (which may leave a company's products out-of-date); (4) government intervention or excessive regulation, delays to approvals or lack of financial support; and (5) legal attacks from competitors.

Other risks: (1) The Fund also invests in small publicly traded companies which may be less mature and more vulnerable to adverse business or economic events and greater share price changes than larger companies, the wider technology sector or stock market. (2) The Fund invests in global equity securities and there is a risk of loss arising from exchange rate fluctuations or exchange control regulations. (3) The ICAV's depository or other service providers may go bankrupt and fail to return money or property belonging to the Fund. (4) It may not always be possible to buy and sell the Fund's shares on a stock exchange or at prices closely reflecting the Fund's Net Asset Value. (5) There is no capital guarantee or protection on the value of the Fund and investors can lose all the capital invested in the Fund.

### Performance scenarios

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted. The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product / a suitable benchmark over the last 10 years. Markets could develop very differently in the future.

| Recommended minimum holding period: 5 years<br>Investment 10 000 USD                           |                                     |                          |   |
|--|-------------------------------------|--------------------------|---|
| Survival Scenarios   |                                     |                          |   |
| Minimum: There is no minimum guaranteed return. You could lose some or all of your investment. |                                     | If you exit after 1 year | If you exit after 5 years<br>(recommended holding period) |
| Stress scenario  | What might you get back after costs | 1 150 USD                | <b>330 USD</b>  |
|  | Average return each year            | -88.53 %                 | - 49.57 %   |
| Unfavourable scenario  | What might you get back after costs | 3 410 USD                | <b>2 390 USD</b>  |
|  | Average return each year            | -65.93 %                 | - 24.91 %   |
| Moderate scenario  | What might you get back after costs | 10 580 USD               | <b>12 720 USD</b>   |
|  | Average return each year            | 5.83 %                   | 4.93 %  |
| Favourable scenario  | What might you get back after costs | 31 160 USD               | <b>60 440 USD</b>   |
|  | Average return each year            | 211.56 %                 | 43.3 %  |

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

The stress scenario shows what you might get back in extreme market circumstances.

Unfavourable: This type of scenario occurred for an investment between 02/2021 and 06/2025.

Moderate: This type of scenario occurred for an investment between 12/2017 and 11/2022.

Favourable: This type of scenario occurred for an investment between 02/2016 and 01/2021.

## WHAT HAPPENS IF IQ EQ FUND MANAGEMENT (IRELAND) LIMITED IS UNABLE TO PAY OUT?

The Fund is a sub-fund of ARK Invest UCITS ICAV (the "ICAV"), an umbrella Irish collective asset-management vehicle which is a separate entity distinct from IQEQ Fund Management (Ireland) Limited (the "Manager"). The assets of the Fund are held in safekeeping by the ICAV's depository, Northern Trust Fiduciary Services (Ireland) Limited (the "Depository"). In the event of the insolvency of the Manager, the Fund's assets in the safekeeping of the Depository will not be affected. However, in the event of the Depository's insolvency, or someone acting on its behalf, the Fund may suffer a financial loss. However, this risk is mitigated to a certain extent by the fact the Depository is required by law and regulation to segregate its own assets from the assets of the Fund. The Depository will also be liable to the Fund and the investors for any loss arising from, among other things, its fraud, wilful default (intentional failure to perform its obligations) or negligence. As a shareholder in the Fund, there is no compensation or guarantee scheme in place.

## WHAT ARE THE COSTS?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment. We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

### Costs over Time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods:

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.

- USD 10 000 is invested.

| Investment 10 000 USD | If you exit after 1 year | If you exit after 5 years |
|-----------------------|--------------------------|---------------------------|
| Total costs           | 79 USD                   | 513 USD                   |
| Annual Cost Impact*   | 0.79 %                   | 0.83 %                    |

\*This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 5.76% before costs and 4.93% after costs.

## Composition of Costs

| One-off costs upon entry or exit                            |   | If you exit after 1 year |
|---|---|--------------------------|
| Entry costs   | 0% We do not charge an entry fee for this product.  | N/A                      |
| Exit costs  | 0% We do not charge an exit fee for this product.   | N/A                      |
| Ongoing costs   |   |                          |
| Management fees and other administrative or operating costs | 0.75% of the value of your investment per year. The ongoing charges are the running costs of the product, including distribution and marketing, but exclude portfolio transaction costs.                                      | 76 USD                   |
| Portfolio transaction costs                                 | 0.04% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell. | 4 USD                    |
| Incidental costs taken under specific conditions            |   |                          |
| Performance Fee   | There is no performance fee for this product.   | N/A                      |

## HOW LONG SHOULD I HOLD IT AND CAN I TAKE MY MONEY OUT EARLY?

Recommended minimum holding period: 5 years

The above mentioned period has been defined in accordance to the product characteristics. It is determined on the basis of the product's risk and reward profile. Your ideal holding period may be different from this minimum recommended holding period. We recommend that you discuss this with your advisor. If the holding period is shorter than the recommended minimum, this may have a negative impact on the product's risk and reward profile. Shares in the product can be sold by ordinary investors using an intermediary (e.g. a stockbroker, or retail investment platform) when the stock markets on which the shares are traded are open. An intermediary is likely to apply a commission to purchases and sales of shares in the product.

## HOW CAN I COMPLAIN?

Complaints made be submitted to the Manager, IQ EQ Fund Management (Ireland) Limited, by email (ManCo@iqeq.com) or telephone (+353 1 673 5480).

## OTHER RELEVANT INFORMATION

- Fund Depository: Northern Trust Fiduciary Services (Ireland) Limited.
- This product is one of a number of sub-funds of ARK Invest UCITS ICAV (the "ICAV"). The assets and liabilities of each sub-fund are segregated from each other by Irish law. Although the rights of investors and creditors are normally limited to the assets of each sub-fund, the ICAV is a single legal entity that may operate in jurisdictions which may not recognise such segregation.
- The ICAV is resident in Ireland for taxation purposes. This may have an impact on your personal tax position. Please consult your investment or tax adviser for advice on your own tax liabilities.
- The Manager may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the ICAV's Prospectus.
- Switching of shares between this Share Class and other share classes of the product and/or other sub-funds of the ICAV is not permitted.
- Further information about this product and the Share Class can be obtained from the ICAV's Prospectus and Fund Supplement.
- Details of the Manager's up-to-date policy in respect of remuneration, including a description of how remuneration and benefits are calculated and the identities of the persons responsible for awarding same can be accessed from the following website: [www.iqeq.com/policy-documents](http://www.iqeq.com/policy-documents)
- The past performances of this product can be found here [https://api.kneip.com/v1/documentdata/permalinks/KPP\\_IE00005M6XO1\\_en\\_CH.pdf](https://api.kneip.com/v1/documentdata/permalinks/KPP_IE00005M6XO1_en_CH.pdf). Please note that past performance is not indicative of future performance. It cannot provide a guarantee of returns that you will receive in the future.
- The previous scenarios document for this product can be found here [https://api.kneip.com/v1/documentdata/permalinks/KMS\\_IE00005M6XO1\\_en\\_CH.xlsx](https://api.kneip.com/v1/documentdata/permalinks/KMS_IE00005M6XO1_en_CH.xlsx)
- The representative in Switzerland is 1741 Fonds Solutions AG. The Paying Agent in Switzerland is Tellco Bank Ltd. The prospectus, the KIIDs and the memorandum and articles of association as well as the annual and semi-annual reports are available free of charge from the representative available. The place of performance and jurisdiction is the registered office of Representative of the Company in Switzerland.